Elevance Health, Inc. $ELV Stock Holdings Lifted by Hosking Partners LLP

Hosking Partners LLP increased its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 1.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 144,548 shares of the company’s stock after buying an additional 2,166 shares during the quarter. Elevance Health comprises approximately 1.7% of Hosking Partners LLP’s portfolio, making the stock its 19th largest holding. Hosking Partners LLP’s holdings in Elevance Health were worth $50,671,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the stock. Family Legacy Inc. boosted its holdings in shares of Elevance Health by 0.7% during the fourth quarter. Family Legacy Inc. now owns 7,439 shares of the company’s stock worth $2,608,000 after purchasing an additional 55 shares during the period. Firetrail Investments PTY Ltd. boosted its holdings in shares of Elevance Health by 16.2% during the fourth quarter. Firetrail Investments PTY Ltd. now owns 30,755 shares of the company’s stock worth $10,834,000 after purchasing an additional 4,291 shares during the period. Income Insurance Ltd bought a new position in Elevance Health during the fourth quarter valued at approximately $234,000. Advisor OS LLC raised its position in Elevance Health by 3.3% during the fourth quarter. Advisor OS LLC now owns 1,830 shares of the company’s stock valued at $642,000 after acquiring an additional 58 shares in the last quarter. Finally, Midwest Trust Co raised its position in Elevance Health by 4.7% during the fourth quarter. Midwest Trust Co now owns 898 shares of the company’s stock valued at $315,000 after acquiring an additional 40 shares in the last quarter. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently weighed in on ELV. The Goldman Sachs Group raised their price objective on shares of Elevance Health from $350.00 to $370.00 and gave the company a “neutral” rating in a research report on Friday, April 24th. Leerink Partners set a $364.00 price objective on shares of Elevance Health in a research report on Thursday, April 23rd. Bank of America raised shares of Elevance Health from a “neutral” rating to a “buy” rating and raised their price objective for the company from $405.00 to $435.00 in a research report on Wednesday, April 29th. Guggenheim raised their price objective on shares of Elevance Health from $396.00 to $399.00 and gave the company a “buy” rating in a research report on Friday, April 24th. Finally, Barclays raised their price objective on shares of Elevance Health from $393.00 to $408.00 and gave the company an “overweight” rating in a research report on Friday, April 24th. Thirteen investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $384.58.

Elevance Health Stock Down 0.1%

ELV opened at $377.66 on Monday. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $424.24. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48. The firm’s fifty day moving average price is $312.92 and its two-hundred day moving average price is $332.13. The company has a market capitalization of $82.01 billion, a P/E ratio of 16.06, a P/E/G ratio of 2.15 and a beta of 0.66.

Elevance Health (NYSE:ELV) last issued its earnings results on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, beating the consensus estimate of $10.74 by $1.84. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The company had revenue of $49.49 billion for the quarter, compared to the consensus estimate of $48.21 billion. During the same quarter in the previous year, the company earned $11.97 EPS. The firm’s revenue for the quarter was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. On average, analysts anticipate that Elevance Health, Inc. will post 26.79 EPS for the current year.

Elevance Health Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Wednesday, June 10th will be issued a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a yield of 1.8%. The ex-dividend date of this dividend is Wednesday, June 10th. Elevance Health’s payout ratio is currently 29.26%.

Elevance Health News Roundup

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Elevance beat first-quarter expectations and raised EPS guidance, which is helping support investor confidence in the company’s near-term outlook. A Look At Elevance Health (ELV) Valuation After Q1 Beat And Raised EPS Guidance
• Positive Sentiment: Zacks Research lifted FY2026 EPS estimates to $26.79 from $25.53, matching the consensus estimate and signaling stronger expected earnings this year.
• Positive Sentiment: Zacks also raised FY2027 EPS estimates to $28.51 from $28.40, and increased its Q2 2027 forecast to $7.23 from $7.20, suggesting analysts still see healthy longer-term profitability.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.